Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

elotuzumab

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen appoints R Sanders Williams to board of directors

He is president of Gladstone Institutes

- PMLiVE

Amgen files lawsuit to block PCSK9 rivals

Firm suing Sanofi and Regeneron for patent infringement

Sanofi reception

Sanofi to work with Immune Design on herpes vaccine

Both companies have separate vaccines in development but will pool resources

- PMLiVE

Amgen leukaemia drug gets FDA priority review

Adds to breakthrough status for blinatumomab

- PMLiVE

Amgen biosimilar matches AbbVie’s Humira in psoriasis trial

ABP 501 set to compete with world’s biggest-selling drug

Eli Lilly HQ

Lilly drops tabalumab after lupus joins arthritis on failure list

Firm said it would take a $75m charge in the fourth quarter

- PMLiVE

Johnson & Johnson to acquire Alios BioPharma for $1.75bn

Will gain access to the biopharma's portfolio of viral infection candidates

- PMLiVE

Merck & Co plays catch-up with osteoporosis data for odanacatib

Says study shows significant reduced risk of osteoporotic symptoms

- PMLiVE

Amgen files breakthrough leukaemia antibody in US

Already received top status from the FDA for the treatment of ALL

National Institute for Health and Care Excellence NICE logo

NICE wants greater access to clinical data

Will turn to European regulators if companies fail to provide information

- PMLiVE

J&J fast-tracks Ebola vaccine

Human clinical trials set to begin in early 2015

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links